Publications by authors named "Y Aydinok"
Article Synopsis
- β-Thalassemia is a lifelong inherited blood disorder that requires ongoing management and leads to significant indirect costs and a burden on patients and caregivers.
- The study conducted a systematic review of the literature from 2010 to 2020, including 75 publications, to assess health-related quality of life (HRQoL) and costs associated with the condition.
- Results showed that patients lose an average of 15.6 to 35 days yearly due to transfusion-related absenteeism, and those with non-transfusion-dependent β-thalassemia experience worse HRQoL compared to those with transfusion-dependent forms, highlighting a need for better treatments.
Objectives: In congenital hemolytic anemias (CHA), it is not always possible to determine the specific diagnosis by evaluating clinical findings and conventional laboratory tests. The aim of this study is to evaluate the utility of next-generation sequencing (NGS) and clinical-exome-based copy number variant (CNV) analysis in patients with CHA.
Methods: One hundred and forty-three CHA cases from 115 unrelated families referred for molecular analysis were enrolled in the study.
CALYPSO (clinicaltrials gov. Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets (DT) in pediatric patients with iron overload. Iron chelation therapy-naive and iron chelation therapy-pretreated patients aged 2 to <18 years with transfusion- dependent anemias were enrolled.
View Article and Find Full Text PDFCombination chelation therapies are considered in transfusion-dependent thalassemia patients for whom monotherapy regimens have failed to achieve iron balance or intensification of iron chelation therapy is required for the rapid reduction of excess iron to avoid permanent organ damage. Combination chelation may provide a more flexible approach for individualizing chelation therapy, thereby improving tolerability, adherence, and quality of life. In principle, iron chelators can be combined with an infinite number of dosing regimens; these involve simultaneous or sequential exposure to the chelators on the same day or alternating the drugs on different days.
View Article and Find Full Text PDFObjective: Invasive fungal infections (IFIs) remain a significant cause of morbidity and mortality in children with acute myeloid leukemia (AML). This study aimed to evaluate the incidence, risk factors, etiology, and outcome of IFIs in children with AML and the effect of mold-active antifungal prophylaxis.
Materials And Methods: We retrospectively reviewed pediatric patients treated for AML between January 2004 and December 2022.